Johnson & Johnson was convicted of $ 8 billion Punitive damages to pay A case concerning the way of marketing the antipsychotic Risperdal. Some male patients have argued that the drug has caused them to grow large breasts and that the company downplayed this side effect in marketing the drug to physicians.
The payout of $ 8 billion, which could later be lowered, was decided by a jury in Philadelphia on Tuesday, according to a New York Times report. Claims for damages against Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, were granted as early as 2016 and, according to the Times, were comparatively low at $ 680,000.
Nicholas Murray, the plaintiff, took Risperdal in 2003 at the age of just 9 years old to treat symptoms related to autism. Murray is said to be up to breasts, and the lawsuit alleged that the full extent of the side effects had not been duly reported to physicians. Murray's attorney team represents about 10,000 other clients who make similar allegations against Johnson & Johnson.
Johnson & Johnson did not respond Wednesday morning to Gizmodo's request for comment, but told the New York Times that it would work to end the "excessive and unfounded verdict." "
" The jury has not received any evidence that the label for Risperdal clearly and adequately explains the risks associated with the drug or the benefits that Risperdal provides for patients with severe mental illness, "said Johnson & Johnson New York Times in a statement. In addition, the applicant's lawyers have not provided any evidence that the applicant was actually harmed by the alleged conduct.
Risperdal was approved by the FDA in 1993 for the treatment of schizophrenia and approved in 2003 for the treatment of bipolar disorder symptoms of autism in 2006.